Lupin’s generic AndroGel gets tentative approval
Get great content like this right in your inbox.
Subscribe

The Food and Drug Administration has granted Lupin tentative approval for its generic AndroGel (testosterone gel, 1.62%). The drug is indicated as a replacement therapy in males for conditions associated with deficiency or absence of endogenous testosterone.
Lupin’s generic AndroGel will be available in a dosage strength of a 20.25 mg/1.25 gm actuation. The drug had U.S. sales of $956.9 million for the 12 months ended January 2018.
Lupin’s generic AndroGel will be available in a dosage strength of a 20.25 mg/1.25 gm actuation. The drug had U.S. sales of $956.9 million for the 12 months ended January 2018.